EUVIMEDEUVIMED entdecken
Crossref

Sulfonamide‐incorporated bis(α‐aminophosphonates) as promising carbonic anhydrase inhibitors: Design, synthesis, biological evaluation, and X‐ray crystallographic studies

Marjan Sobati, Morteza Abdoli, Andrea Angeli, Alessandro Bonardi, Marta Ferraroni, Claudiu T Supuran, Raivis Žalubovskis

Archiv der Pharmazie · 2024

DOI: 10.1002/ardp.202400038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Marjan Sobati und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemistry and Chemical Technology, Faculty of Natural Sciences and Technology, Riga Technical University, Riga, Latvia. Hauptthemen laut MEDLINE: Carbonic Anhydrase Inhibitors, Sulfonamides, Drug Design, Carbonic Anhydrases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A novel series of sulfonamide‐incorporated bis(α‐aminophosphonates) acting as effective carbonic anhydrase (CA, EC 4.2.1.1) inhibitors is reported. The synthesized bivalent ligands were tested against five human (h) isoforms, hCA I, hCA II, hCA VII, hCA IX, and hCA XIII. Such derivatives showed high activity and selectivity against the cancer‐related, membrane‐bound isoform hCA IX, and among them, compound 5h , tetraisopropyl (1,3‐phenylenebis{[(4‐sulfamoylphenyl)amino]methylene})bis(phosphonate) showed a K I of 15.1 nM, being highly selective against this isoform over all other investigated ones (hCA I/IX = 42; hCA II/IX = 6, hCA VII/IX = 3, hCA XIII/IX = 5). Therefore, compound 5h could be a potential lead for the development of selective anticancer agents. The newly developed sulfonamides were also found effective inhibitors against the cytosolic hCA XIII isoform. Compound 5i displayed the best inhibition against this isoform with a K I of 17.2 nM, equal to that of the well‐known inhibitor acetazolamide (AAZ), but significantly more selective over all other tested isoforms (hCA I/XIII = 239; hCA II/XIII = 23, hCA VII/XIII = 2, hCA IX/XIII = 3) compared to AAZ.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carbonic Anhydrase InhibitorsSulfonamidesDrug DesignCarbonic AnhydrasesHumansStructure-Activity RelationshipCrystallography, X-RayMolecular StructureIsoenzymesAntineoplastic AgentsOrganophosphonatesDose-Response Relationship, Drug

Stichwörter der Autor:innen

bis‐sulfonamidescarbonic anhydrasescrystallographymultivalencyα‐aminophosphonates

Substanzen

Carbonic Anhydrase InhibitorsSulfonamidesCarbonic AnhydrasesIsoenzymesAntineoplastic AgentsOrganophosphonates

Autor:innen und Institutionen

  • Institute of Chemistry and Chemical Technology, Faculty of Natural Sciences and Technology, Riga Technical University, Riga, Latvia.
  • Neurofarba Department, Pharmaceutical and Nutraceutical Section, University of Florence, Florence, Italy.
  • Dipartimento di Chimica "Ugo Schiff", University of Florence, Florence, Italy.
  • Latvian Institute of Organic Synthesis, Riga, Latvia.

Förderung

  • None

Zitieren

APA

Sobati, M., Abdoli, M., Angeli, A., Bonardi, A., Ferraroni, M., Supuran, C. T., & Žalubovskis, R. (2024). Sulfonamide‐incorporated bis(α‐aminophosphonates) as promising carbonic anhydrase inhibitors: Design, synthesis, biological evaluation, and X‐ray crystallographic studies. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400038

Vancouver

Sobati M, Abdoli M, Angeli A, Bonardi A, Ferraroni M, Supuran CT, et al. Sulfonamide‐incorporated bis(α‐aminophosphonates) as promising carbonic anhydrase inhibitors: Design, synthesis, biological evaluation, and X‐ray crystallographic studies. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202400038

BibTeX
@article{Sobati2024,
  author = {Sobati, Marjan and Abdoli, Morteza and Angeli, Andrea and Bonardi, Alessandro and Ferraroni, Marta and Supuran, Claudiu T and Žalubovskis, Raivis},
  title = {Sulfonamide‐incorporated bis(α‐aminophosphonates) as promising carbonic anhydrase inhibitors: Design, synthesis, biological evaluation, and X‐ray crystallographic studies},
  journal = {Archiv der Pharmazie},
  year = {2024},
  doi = {10.1002/ardp.202400038}
}
Kostenlos starten →